What Is Pregabalin?

Pregabalin (brand name Lyrica) is an anticonvulsant medication that's FDA-approved for several chronic pain conditions. It's related to gabapentin but has more predictable absorption and may work faster. It's commonly used for neuropathic pain, fibromyalgia, and certain seizure disorders.1

FDA-Approved Indications

  • Diabetic peripheral neuropathy
  • Postherpetic neuralgia (shingles pain)
  • Fibromyalgia
  • Spinal cord injury pain
  • Partial seizures (adjunct)
  • Generalized anxiety disorder (Europe)

How It Works2

  • Binds to calcium channels in nerves
  • Reduces release of excitatory neurotransmitters
  • Calms overactive nerve signaling
  • More linear absorption than gabapentin

Dosing3

  • Usually start at 75 mg twice daily
  • May increase to 150 mg twice daily
  • Maximum: 300 mg twice daily (600 mg/day)
  • Adjust for kidney function
  • Takes 1-2 weeks for effect

Common Side Effects

  • Dizziness
  • Drowsiness
  • Weight gain
  • Dry mouth
  • Peripheral edema (swelling)
  • Blurred vision
  • Difficulty concentrating

Serious Side Effects

  • Suicidal thoughts (rare)
  • Severe allergic reactions
  • Angioedema
  • Respiratory depression (with opioids)

Important Information

  • Controlled substance (Schedule V)
  • Potential for misuse/dependence
  • Don't stop suddenly—taper gradually
  • Avoid alcohol
  • May impair driving

Pregabalin vs. Gabapentin

  • Pregabalin: more predictable absorption
  • Pregabalin: may work faster
  • Pregabalin: twice daily dosing
  • Gabapentin: less expensive
  • Effectiveness similar for many

Drug Interactions

  • Opioids (increased sedation, respiratory risk)
  • Alcohol
  • Benzodiazepines
  • Other CNS depressants

Effectiveness

  • Helps about 30-50% of patients significantly
  • Modest average pain reduction
  • Response varies by individual
  • Give adequate trial before discontinuing

References

  1. Derry S, Bell RF, Straube S, et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1:CD007076.
  2. Bockbrader HN, Wesche D, Miller R, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661-669.
  3. Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf. 2014;5(1):38-56.